About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 205948, 9 pages
http://dx.doi.org/10.1155/2013/205948
Research Article

Urine Bikunin as a Marker of Renal Impairment in Fabry's Disease

1Dipartimento di Scienze Biomediche, University of Sassari, Via Muroni 25, 07100 Sassari, Italy
2Dipartimento di Medicina Clinica e Sperimentale, University of Sassari, Viale San Pietro 10, 07100 Sassari, Italy
3Unità Operativa di Pediatria Universitaria, Azienda Ospedaliera “Pugliese-Ciaccio”, Viale Pio X, 88100 Catanzaro, Italy

Received 22 February 2013; Revised 2 May 2013; Accepted 20 May 2013

Academic Editor: Achilleas D. Theocharis

Copyright © 2013 Antonio Junior Lepedda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. A. Zarate and R. J. Hopkin, “Fabry's disease,” The Lancet, vol. 372, no. 9647, pp. 1427–1435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Desnick and R. O. Brady, “Fabry disease in childhood,” Journal of Pediatrics, vol. 144, no. 5, Supplement, pp. S20–S26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Breunig and C. Wanner, “Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy,” Journal of Nephrology, vol. 21, no. 1, pp. 32–37, 2008. View at Scopus
  4. R. Schiffmann, “Fabry disease,” Pharmacology and Therapeutics, vol. 122, no. 1, pp. 65–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Torralba-Cabeza, S. Olivera, D. A. Hughes, G. M. Pastores, R. N. Mateo, and J. Pérez-Calvo, “Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease,” Molecular Genetics and Metabolism, vol. 104, no. 3, pp. 301–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Esko, K. Kimata, and U. Lindahl, “Proteoglycans and sulfated glycosaminoglycans,” in Essential of Glycobiology, A. Varki, R. D. Cummings, J. D. Esko, et al., Eds., Chapter 16, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2nd edition, 2009.
  7. M. Ly, F. E. Leach, T. N. Laremore, T. Toida, I. J. Amster, and R. J. Linhardt, “The proteoglycan bikunin has a defined sequence,” Nature Chemical Biology, vol. 7, no. 11, pp. 827–833, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Zinellu, S. Pisanu, E. Zinellu et al., “A novel LIF-CE method for the separation of hyalurnan- and chondroitin sulfate-derived disaccharides: application to structural and quantitative analyses of human plasma low- and high-charged chondroitin sulfate isomers,” Electrophoresis, vol. 28, no. 14, pp. 2439–2447, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Zinellu, A. J. Lepedda, A. Cigliano et al., “Association between human plasma chondroitin sulfate isomers and carotid atherosclerotic plaques,” Biochemistry Research International, vol. 2012, Article ID 281284, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Zhuo, V. C. Hascall, and K. Kimata, “Inter-α-trypsin inhibitor, a covalent protein-glycosaminoglycan- protein complex,” Journal of Biological Chemistry, vol. 279, no. 37, pp. 38079–38082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Matsuzaki, H. Kobayashi, T. Yagyu et al., “Plasma bikunin as a favorable prognostic factor in ovarian cancer,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1463–1472, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. De Muro, R. Faedda, A. Satta et al., “Urinary glycosaminoglycan composition in chronic glomerulonephritis,” Journal of Nephrology, vol. 18, no. 2, pp. 154–160, 2005. View at Scopus
  13. P. De Muro, R. Faedda, A. E. Satta et al., “Quali-quantitative analysis of urinary glycosaminoglycans for monitoring glomerular inflammatory activity,” Scandinavian Journal of Urology and Nephrology, vol. 41, no. 3, pp. 230–236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. P. De Muro, R. Faedda, A. Masala et al., “Kidney post-transplant monitoring of urinary glycosaminoglycans/proteoglycans and monokine induced by IFN-γ (MIG),” Clinical and Experimental Medicine, vol. 13, no. 1, pp. 59–65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. P. De Muro, P. Fresu, G. Tonolo et al., “A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 5, pp. 561–567, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. P. De Muro, R. Faedda, M. Formato et al., “Urinary glycosaminoglycans in patients with systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 19, no. 2, pp. 125–130, 2001. View at Scopus
  17. P. De Muro, G. Capobianco, M. Formato et al., “Glycosaminoglycan and transforming growth factor β1 changes in human plasma and urine during the menstrual cycle, in vitro fertilization treatment, and pregnancy,” Fertility and Sterility, vol. 92, no. 1, pp. 320–327, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. J. Pugia, R. Valdes Jr., and S. A. Jortani, “Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement,” Advances in Clinical Chemistry, vol. 44, pp. 223–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. De Lin, R. Endo, H. Kuroda et al., “Plasma and urine levels of urinary trypsira inhibitor in patients with chronic liver diseases and hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 19, no. 3, pp. 327–332, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Sakai, H. Okudera, and K. Hongo, “Significant elevation of urinary trypsin inhibitor in patients with brain contusion—a preliminary report,” Journal of Clinical Neuroscience, vol. 10, no. 6, pp. 677–679, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Bitter and H. M. Muir, “A modified uronic acid carbazole reaction,” Analytical Biochemistry, vol. 4, no. 4, pp. 330–334, 1962. View at Scopus
  22. R. Cappelletti, M. Del Rosso, and V. P. Chiarugi, “A new electrophoretic method for the complete separation of all known animal glycosaminoglycans in a monodimensional run,” Analytical Biochemistry, vol. 99, no. 2, pp. 311–315, 1979. View at Scopus
  23. A. Zinellu, A. Lepedda Jr., S. Sotgia et al., “Albumin-bound low molecular weight thiols analysis in plasma and carotid plaques by CE,” Journal of Separation Science, vol. 33, no. 1, pp. 126–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. H. Branton, R. Schiffmann, S. G. Sabnis et al., “Natural history of fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course,” Medicine, vol. 81, no. 2, pp. 122–138, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Mehta, M. Beck, P. Elliott et al., “Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data,” The Lancet, vol. 374, no. 9706, pp. 1986–1996, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. G. Warnock and M. L. West, “Diagnosis and management of kidney involvement in fabry disease,” Advances in Chronic Kidney Disease, vol. 13, no. 2, pp. 138–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Ries, J. T. R. Clarke, C. Whybra et al., “Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease,” Pediatrics, vol. 118, no. 3, pp. 924–932, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Schiffmann, S. Waldek, A. Benigni, and C. Auray-Blais, “Biomarkers of fabry disease nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 2, pp. 360–364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Ortu, L. Fancellu, G. Sau et al., “Primary motor cortex hyperexcitability in Fabry's disease,” Clinical Neurophysiology, 2013. View at Publisher · View at Google Scholar
  30. A. C. Vedder, É. Biró, J. M. F. G. Aerts, R. Nieuwland, G. Sturk, and C. E. M. Hollak, “Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment,” Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 3074–3081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Kikumoto, Y. Kai, H. Morinaga et al., “Fabry disease exhibiting recurrent stroke and persistent inflammation,” Internal Medicine, vol. 49, no. 20, pp. 2247–2252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. H. Futerman and G. Van Meer, “The cell biology of lysosomal storage disorders,” Nature Reviews Molecular Cell Biology, vol. 5, no. 7, pp. 554–565, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. E. B. Vitner, F. M. Platt, and A. H. Futerman, “Common and uncommon pathogenic cascades in lysosomal storage diseases,” Journal of Biological Chemistry, vol. 285, no. 27, pp. 20423–20427, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Itoh, M. Tomita, T. Kobayashi, H. Uchino, H. Maruyama, and Y. Nawa, “Expression of inter-α-trypsin inhibitor light chain (bikunin) in human pancreas,” Journal of Biochemistry, vol. 120, no. 2, pp. 271–275, 1996. View at Scopus